E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with viral respiratory tract infection (influenza virus, parainfluenza virus, respiratory syncytial virus or human metapneumovirus) |
|
E.1.1.1 | Medical condition in easily understood language |
Airway infections caused by respiratory virus (influenza virus, parainfluenza virus, respiratory syncytial virus or human metapneumovirus) |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary aim is to assess whether discontinuation of antibiotic therapy in patients with positive airway sample for respiratory viruses is safe and associated with early clinical response assessed at 120 hours after hospital admission that is comparable to patients who continue antibiotic therapy. |
|
E.2.2 | Secondary objectives of the trial |
The secondary aims are to assess whether discontinuation of antibiotic therapy in patients with positive airway sample for respiratory viruses is associated comparable (1) mortality rates, (2) duration of hospital admission, (3) defined daily doses of antibiotic therapy. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1. Hospitalized 2. Adults 18 year or older 3. Moderately severe disease (CRB65 ≤ 2 at time of inclusion) 4. Nasopharyngeal swab positive for influenza virus, parainfluenza virus, respiratory syncytial virus (RSV) or human metapneumovirus (hMPV) 5. On antibiotic therapy as instituted by the receiving physician from the emergency department 6. Signed informed consent must be obtained and documented according to ICH GCP, and national/local regulations.
|
|
E.4 | Principal exclusion criteria |
1. Requiring ICU admission at screening 2. Requiring high-flow oxygen therapy or non-invasive ventilation at screening 3. Signs of severe pneumonia (abscesses, massive pleural effusion, a well-defined lobar infiltrate on chest X-ray strongly suggestive of bacterial etiology) 4. Not immunocompetent (i.e. on active chemotherapy, corticosteroid therapy equaling ≥ 20 mg prednisolone daily for ≥ 4 weeks, chronic immunosuppression due to solid organ transplant) 5. SARS-CoV-2 positive 6. Bacteremia 7. Urine antigen test positive for legionella 8. Any other infection necessitating antibiotic treatment 9. Antibiotic use for assumed airway infection within the last 24 hours before admission to hospital 10. Time from initiation of antibiotic therapy to screening >48 hours |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Early clinical response, quantified as survival with symptom improvement without receipt of rescue antibacterial therapy. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
120 hours after admission |
|
E.5.2 | Secondary end point(s) |
1. Duration of hospital admission 2. In-hospital mortality 3. 30 day mortality 4. Days of therapy with antibiotics 5. In-hospital rescue antibiotic therapy 6. New antibiotic therapy for assumed airway infection within 30 days after discharge 7. Hospital readmissions up to 30 days after discharge
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
In-hospital end points - during hospital admission 30-day end points - at 30 days after hospital discharge |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
Two-arm, open label, pragmatic randomized controlled non-inferiority stop trial |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
Standard of care (no placebo control) |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |